{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:36Z","timestamp":1772136396178,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2011\/17341-0"],"award-info":[{"award-number":["2011\/17341-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/22140-7"],"award-info":[{"award-number":["2016\/22140-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["304666\/2022-0"],"award-info":[{"award-number":["304666\/2022-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Experimental studies have shown that urinary dipeptidyl peptidase 4 (uDPP4), unlike serum DPP4 (sDPP4) activity, correlates with proteinuria, serum creatinine, and left ventricular (LV) hypertrophy in chronic kidney disease (CKD) models, suggesting a potential role for uDPP4 in CKD progression. This study examined the relationship of uDPP4 and sDPP4 activities with renal, cardiovascular, and metabolic markers, along with mortality and initiation of kidney replacement therapy (KRT) events in individuals with CKD. DPP4 activity was measured in the urine and serum of 426 participants from the Brazilian CKD cohort, PROGREDIR. Participants were stratified into tertiles based on uDPP4 and sDPP4 activities. Multivariable linear regression, Kaplan\u2013Meier analysis, Cox hazards, and competing risk models (cause-specific and Fine\u2013Gray) were used. uDPP4 activity was positively associated with albuminuria, urinary retinol-binding protein 4, LV mass, and type 2 diabetes but inversely associated with body mass index and use of renin-angiotensin system blockers. In contrast, sDPP4 activity correlated only with age and biological sex. Higher uDPP4 activity was associated with a higher incidence rate of all-cause mortality (p\u2009&lt;\u20090.0001). Participants in the second and third uDPP4 activity tertiles had greater mortality risk compared to the lowest tertile (HR 2.03, 95% CI 1.36\u20133.04 and HR 2.48, 95% CI 1.67\u20133.67, respectively), even after controlling for potential confounders. No independent association was found between sDPP4 activity and mortality or initiation of KRT. These findings support uDPP4\u2019s involvement in CKD progression and its association with increased mortality risk in individuals with CKD.<\/jats:p>","DOI":"10.1038\/s41598-025-06395-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:42:45Z","timestamp":1751413365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of urinary dipeptidyl peptidase 4 activity with clinical outcomes in people with chronic kidney disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Acaris","family":"Benetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao Carlos","family":"Ribeiro-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz M.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio A. M.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela J.","family":"Bensenor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo A.","family":"Lotufo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia M. O.","family":"Titan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C. C.","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"3","key":"6395_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir, A. M., Durinx, C., Scharp\u00e9, S. & De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40(3), 209\u2013294 (2003).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"6395_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/bj1570169","volume":"157","author":"AJ Kenny","year":"1976","unstructured":"Kenny, A. J. et al. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem. J. 157(1), 169\u2013182 (1976).","journal-title":"Biochem. J."},{"issue":"9","key":"6395_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon, C. F. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44(9), 1126\u20131131 (1995).","journal-title":"Diabetes"},{"issue":"3","key":"6395_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","volume":"214","author":"R Mentlein","year":"1993","unstructured":"Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214(3), 829\u2013835 (1993).","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"6395_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0167-0115(93)90435-B","volume":"49","author":"R Mentlein","year":"1993","unstructured":"Mentlein, R., Dahms, P., Grandt, D. & Kr\u00fcger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49(2), 133\u2013144 (1993).","journal-title":"Regul. Pept."},{"issue":"11","key":"6395_CR6","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1073\/pnas.95.11.6331","volume":"95","author":"T Shioda","year":"1998","unstructured":"Shioda, T. et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26\/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. U.S.A. 95(11), 6331\u20136336 (1998).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5120","key":"6395_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.8101391","volume":"261","author":"J Kameoka","year":"1993","unstructured":"Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F. & Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261(5120), 466\u2013469 (1993).","journal-title":"Science"},{"issue":"49","key":"6395_CR8","doi-asserted-by":"publisher","first-page":"46671","DOI":"10.1074\/jbc.M106897200","volume":"276","author":"ACC Girardi","year":"2001","unstructured":"Girardi, A. C. C., Degray, B. C., Nagy, T., Biemesderfer, D. & Aronson, P. S. Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J. Biol. Chem. 276(49), 46671\u201346677 (2001).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"6395_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/bbrc.1995.2782","volume":"217","author":"K L\u00f6ster","year":"1995","unstructured":"L\u00f6ster, K., Zeilinger, K., Schuppan, D. & Reutter, W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem. Biophys. Res. Commun. 217(1), 341\u2013348 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"6395_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0014-4827(88)90378-3","volume":"178","author":"C Hanski","year":"1988","unstructured":"Hanski, C., Huhle, T., Gossrau, R. & Reutter, W. Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp. Cell Res. 178(1), 64\u201372 (1988).","journal-title":"Exp. Cell Res."},{"issue":"22","key":"6395_CR11","doi-asserted-by":"publisher","first-page":"19532","DOI":"10.1074\/jbc.M004586200","volume":"276","author":"C Herrera","year":"2001","unstructured":"Herrera, C. et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J. Biol. Chem. 276(22), 19532\u201319539 (2001).","journal-title":"J. Biol. Chem."},{"issue":"8","key":"6395_CR12","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4049\/jimmunol.147.8.2514","volume":"147","author":"Y Torimoto","year":"1991","unstructured":"Torimoto, Y. et al. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147(8), 2514\u20132517 (1991).","journal-title":"J. Immunol."},{"issue":"1","key":"6395_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0065-1281(11)80302-8","volume":"91","author":"D Stiller","year":"1991","unstructured":"Stiller, D., Bahn, H. & August, C. Demonstration of glomerular DPP IV activity in kidney diseases. Acta Histochem. 91(1), 105\u2013109 (1991).","journal-title":"Acta Histochem."},{"issue":"21","key":"6395_CR14","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1016\/j.febslet.2014.08.029","volume":"588","author":"D R\u00f6hrborn","year":"2014","unstructured":"R\u00f6hrborn, D., Eckel, J. & Sell, H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and upregulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 588(21), 3870\u20133877 (2014).","journal-title":"FEBS Lett."},{"key":"6395_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.peptides.2014.09.006","volume":"61","author":"A Stengel","year":"2014","unstructured":"Stengel, A. et al. Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 61, 75\u201382 (2014).","journal-title":"Peptides"},{"issue":"9","key":"6395_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1042\/CS20190946","volume":"134","author":"DF Arruda-Junior","year":"2020","unstructured":"Arruda-Junior, D. F. et al. Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure. Clin. Sci. (Lond.) 134(9), 1081\u20131094 (2020).","journal-title":"Clin. Sci. (Lond.)"},{"issue":"6","key":"6395_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","volume":"106","author":"KM Love","year":"2021","unstructured":"Love, K. M. & Liu, Z. DPP4 activity, hyperinsulinemia, and atherosclerosis. J. Clin. Endocrinol. Metab. 106(6), 1553\u20131565 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"6395_CR18","doi-asserted-by":"publisher","first-page":"e0163027","DOI":"10.1371\/journal.pone.0163027","volume":"11","author":"G Yang","year":"2016","unstructured":"Yang, G. et al. Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease. PLoS ONE 11(9), e0163027 (2016).","journal-title":"PLoS ONE"},{"issue":"5","key":"6395_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCHEARTFAILURE.112.000057","volume":"6","author":"L Dos Santos","year":"2013","unstructured":"Dos Santos, L. et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ. Heart Fail. 6(5), 1029\u20131038 (2013).","journal-title":"Circ. Heart Fail."},{"issue":"3","key":"6395_CR20","doi-asserted-by":"publisher","first-page":"F285","DOI":"10.1152\/ajprenal.00288.2020","volume":"320","author":"A Benetti","year":"2021","unstructured":"Benetti, A. et al. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD. Am. J. Physiol. Renal Physiol. 320(3), F285\u2013F296 (2021).","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"5","key":"6395_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.kint.2016.01.016","volume":"89","author":"O Tsuprykov","year":"2016","unstructured":"Tsuprykov, O. et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5\/6 nephrectomy. Kidney Int. 89(5), 1049\u20131061 (2016).","journal-title":"Kidney Int."},{"issue":"8","key":"6395_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20081940","volume":"20","author":"JI Beraldo","year":"2019","unstructured":"Beraldo, J. I. et al. Cardioprotection conferred by sitagliptin is associated with reduced cardiac angiotensin II\/angiotensin-(1\u20137) balance in experimental chronic kidney disease. Int. J. Mol. Sci. 20(8), 1 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"6395_CR23","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.2337\/db13-1029","volume":"63","author":"K Kanasaki","year":"2014","unstructured":"Kanasaki, K. et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63(6), 2120\u20132131 (2014).","journal-title":"Diabetes"},{"issue":"10","key":"6395_CR24","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/oby.20833","volume":"22","author":"R Nistala","year":"2014","unstructured":"Nistala, R. et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) 22(10), 2172\u20132179 (2014).","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"6395_CR25","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1210\/en.2013-1920","volume":"155","author":"R Nistala","year":"2014","unstructured":"Nistala, R. et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 155(6), 2266\u20132276 (2014).","journal-title":"Endocrinology"},{"issue":"4","key":"6395_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2337\/dc14-1850","volume":"38","author":"JA Udell","year":"2015","unstructured":"Udell, J. A. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38(4), 696\u2013705 (2015).","journal-title":"Diabetes Care"},{"issue":"1","key":"6395_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 321(1), 69\u201379 (2019).","journal-title":"JAMA"},{"issue":"32","key":"6395_CR28","doi-asserted-by":"publisher","first-page":"53028","DOI":"10.18632\/oncotarget.18081","volume":"8","author":"CT Chao","year":"2017","unstructured":"Chao, C. T., Wang, J., Wu, H. Y., Chien, K. L. & Hung, K. Y. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget 8(32), 53028\u201353040 (2017).","journal-title":"Oncotarget"},{"issue":"9","key":"6395_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1080\/08860220802359048","volume":"30","author":"B Mitic","year":"2008","unstructured":"Mitic, B., Lazarevic, G., Vlahovic, P., Rajic, M. & Stefanovic, V. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Renal Fail. 30(9), 896\u2013903 (2008).","journal-title":"Renal Fail."},{"issue":"9731","key":"6395_CR30","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375(9731), 2073\u20132081 (2010).","journal-title":"Lancet"},{"issue":"7","key":"6395_CR31","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/ASN.2005101085","volume":"17","author":"M Tonelli","year":"2006","unstructured":"Tonelli, M. et al. Chronic kidney disease and mortality risk: A systematic review. J. Am. Soc. Nephrol. 17(7), 2034\u20132047 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"6395_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cmet.2018.10.001","volume":"29","author":"EM Varin","year":"2019","unstructured":"Varin, E. M. et al. Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition. Cell Metab. 29(2), 320\u2013334 (2019).","journal-title":"Cell Metab."},{"issue":"1","key":"6395_CR33","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1038\/s41467-020-17556-z","volume":"11","author":"LL Baggio","year":"2020","unstructured":"Baggio, L. L. et al. Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nat. Commun. 11(1), 3766 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"6395_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2003.08.111","volume":"310","author":"L Pala","year":"2003","unstructured":"Pala, L. et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem. Biophys. Res. Commun. 310(1), 28\u201331 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"6395_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1479164111434318","volume":"9","author":"AL Sun","year":"2012","unstructured":"Sun, A. L. et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab. Vasc. Dis. Res. 9(4), 301\u2013308 (2012).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"6395_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B. et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell Cardiol. 66, 167\u2013176 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"issue":"5","key":"6395_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms17050780","volume":"17","author":"A Aroor","year":"2016","unstructured":"Aroor, A. et al. Angiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubules. Int. J. Mol. Sci. 17(5), 1 (2016).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"6395_CR38","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1210\/en.2013-1096","volume":"154","author":"AR Aroor","year":"2013","unstructured":"Aroor, A. R. et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 154(7), 2501\u20132513 (2013).","journal-title":"Endocrinology"},{"issue":"4","key":"6395_CR39","doi-asserted-by":"publisher","first-page":"C1203","DOI":"10.1152\/ajpcell.00734.2023","volume":"326","author":"FL Martins","year":"2024","unstructured":"Martins, F. L., Ribeiro-Silva, J. C., Nistala, R. & Girardi, A. C. C. Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling. Am. J. Physiol. Cell Physiol. 326(4), C1203\u2013C1211 (2024).","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"6395_CR40","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1152\/ajprenal.00565.2020","volume":"320","author":"R Nistala","year":"2021","unstructured":"Nistala, R. et al. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. Am. J. Physiol. Renal Physiol. 320(3), F505\u2013F517 (2021).","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"3","key":"6395_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-3083.2001.00984.x","volume":"54","author":"MD Gorrell","year":"2001","unstructured":"Gorrell, M. D., Gysbers, V. & McCaughan, G. W. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54(3), 249\u2013264 (2001).","journal-title":"Scand. J. Immunol."},{"issue":"12","key":"6395_CR42","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.jid.2020.04.010","volume":"140","author":"CA Worthen","year":"2020","unstructured":"Worthen, C. A. et al. CD26 identifies a subpopulation of fibroblasts that produce the majority of collagen during wound healing in human skin. J. Investig. Dermatol. 140(12), 2515\u20132524 (2020).","journal-title":"J. Investig. Dermatol."},{"issue":"8","key":"6395_CR43","doi-asserted-by":"publisher","first-page":"F878","DOI":"10.1152\/ajprenal.00590.2014","volume":"308","author":"Y Higashijima","year":"2015","unstructured":"Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S. & Nangaku, M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am. J. Physiol. Renal Physiol. 308(8), F878\u2013F887 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"5","key":"6395_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/labinvest.2016.34","volume":"96","author":"J Eun Lee","year":"2016","unstructured":"Eun Lee, J. et al. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab Investig. 96(5), 547\u2013560 (2016).","journal-title":"Lab Investig."},{"issue":"1","key":"6395_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4093\/dmj.2018.0030","volume":"43","author":"EH Cho","year":"2019","unstructured":"Cho, E. H. & Kim, S. W. Soluble dipeptidyl peptidase-4 levels are associated with decreased renal function in patients with type 2 diabetes mellitus. Diabetes Metab. J. 43(1), 97\u2013104 (2019).","journal-title":"Diabetes Metab. J."},{"issue":"2","key":"6395_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1515\/CCLM.2001.026","volume":"39","author":"C Durinx","year":"2001","unstructured":"Durinx, C. et al. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 39(2), 155\u2013159 (2001).","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"6395_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/eje.1.02221","volume":"155","author":"J Ryskjaer","year":"2006","unstructured":"Ryskjaer, J. et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 155(3), 485\u2013493 (2006).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"6395_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/1516-3180.2016.0272261116","volume":"135","author":"MAM Domingos","year":"2017","unstructured":"Domingos, M. A. M., Goulart, A. C., Lotufo, P. A., Bense\u00f1or, I. J. M. & Titan, S. M. O. Chronic kidney disease-determinants of progression and cardiovascular risk. PROGREDIR cohort study: Design and methods. Sao Paulo Med. J. 135(2), 133\u20139 (2017).","journal-title":"Sao Paulo Med. J."},{"issue":"7","key":"6395_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jdiacomp.2017.04.013","volume":"31","author":"MAM Domingos","year":"2017","unstructured":"Domingos, M. A. M., Queiroz, M., Lotufo, P. A., Bense\u00f1or, I. J. & Titan, S. M. O. Serum RBP4 and CKD: Association with insulin resistance and lipids. J. Diabetes Complic. 31(7), 1132\u20131138 (2017).","journal-title":"J. Diabetes Complic."},{"issue":"5","key":"6395_CR50","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An update based on rapidly emerging new evidence. Kidney Int. 102(5), 990\u2013999 (2022).","journal-title":"Kidney Int."},{"issue":"6","key":"6395_CR51","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","volume":"57","author":"RB Devereux","year":"1986","unstructured":"Devereux, R. B. et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 57(6), 450\u2013458 (1986).","journal-title":"Am. J. Cardiol."},{"issue":"Suppl 2","key":"6395_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1590\/S0034-8910.2013047003836","volume":"47","author":"SM Barreto","year":"2013","unstructured":"Barreto, S. M. et al. ELSA-Brasil strategies for outcome identification, investigation and ascertainment. Rev. Saude Publ. 47(Suppl 2), 79\u201386 (2013).","journal-title":"Rev. Saude Publ."},{"issue":"3","key":"6395_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00577838","volume":"7","author":"VK Hopsu-Havu","year":"1966","unstructured":"Hopsu-Havu, V. K. & Glenner, G. G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7(3), 197\u2013201 (1966).","journal-title":"Histochemie"},{"issue":"6","key":"6395_CR54","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin, P. C., Lee, D. S. & Fine, J. P. Introduction to the analysis of survival data in the presence of competing risks. Circulation 133(6), 601\u2013609 (2016).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06395-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:14:30Z","timestamp":1751422470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06395-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6395"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06395-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5321224\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tavares CAM reports receiving lecture fees from Novo Nordisk outside the submitted work. No other conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23190"}}